Epizyme Research Chief, Copeland, to Retire

Xconomy Boston — 

Epizyme (NASDAQ: EPZM) said that its longtime president of research and chief scientific officer, Robert Copeland, will retire in the second quarter to “pursue advisory and other opportunities within the industry,” the company said in a statement. Copeland has been at Epizyme since 2008 and will remain a “key advisor” to the company after he leaves.